Personalized Interventions Via Health Portraits in Mild Behavioral Impairment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorFujian Provincial Hospital

About this trial

The incidence of MBI and the probability of progression to dementia are high. Early detection and intervention have important clinical significance to reduce the occurrence of dementia, delay the progression of dementia and promote healthy aging to active aging. The occurrence and development of NPS in MBI patients may be related to genetic and degenerative changes in the central nervous system. The evaluation of MBI patients is mainly based on neuropsychological tests, including NPS and cognitive function assessment. Landmark model is an effective tool for dynamic risk prediction of the progress of MBI. It can make dynamic prediction at different time points according to various existing measurement indicators of an individual and calculate the individual prediction probability, which is one of the best models for studying the outcome of disease at present. The Landmark model is applied to the elderly MBI population to study the influencing factors of normal aging, MBI and dementia and the probability of metastasis, which is a beneficial attempt to further advance the defense line of dementia. Personalized non-drug intervention is the preferred treatment for MBI, which mainly includes cognitive/emotional intervention, sensory stimulation, exercise therapy, etc. Currently, it is recommended to adopt diversified strategies to implement individualized precision treatment programs for patients. The hierarchical and classified health management of elderly MBI patients combined with health portrait technology is helpful to improve management efficiency and better meet the needs of personalized health management for the elderly.

Eligibility criteria

Qualifiers

Meet the ISTAART diagnostic criteria for MBI;

Age ≥60 years old;

No obvious visual or hearing impairment;

Have the ability of language communication, can complete the scale assessment.

Disqualifiers

Patients with severe physical diseases and unable to complete cognitive function screening;

Patients with other neurological diseases and serious medical diseases that can cause brain dysfunction.

Trial design

Treatments tested in this trial

  • Personalized intervention

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators